SRI Surgical Express competitors

Mark T. Bertolini (born 1956) is an American businessman who was the CEO of Aetna, a Fortune 50 diversified health care benefits company with over $60 billion in 2015 revenue. Bertolini assumed the role of CEO on November 29, 2010 and of Chairman on April 8, 2011 until Aetna was sold to CVS on November 28, 2018.

C-Level Executive with demonstrated leadership skills and proven business results in Pharmaceuticals (Branded and Generics), Sales, Marketing, Operations, Business Development, R&D/Regulatory.I'm a creative problem-solver, with a track record of outstanding results through professional and interpersonal skills including strategic vision, team development, people management, prioritization, motivation, decisiveness and grit.

Hervé Hoppenot joined Incyte in 2014 as President and Chief Executive Officer, and was appointed Chairman of the Board of Directors in 2015. During Mr. Hoppenot’s tenure, the Company has tripled the number of clinical candidates in its portfolio, expanding beyond oncology to include research and development in inflammation & autoimmunity. Under his leadership, revenue has increased by over 400 percent, which includes the addition of two new revenue streams; and, with a goal to deliver medicines to patients worldwide, the Company has expanded geographically beyond the U.S. to include operations in 10 EU countries and Japan. Prior to joining Incyte, Mr. Hoppenot was the President of Novartis Oncology. Prior to joining Novartis in 2003, Mr. Hoppenot started his career in 1983 with Rhone Poulenc, later known as Aventis, where he served in several senior roles of increasing responsibility, including Vice President of Oncology and Head of the U.S. Oncology business unit. Mr. Hoppenot holds a diploma from ESSEC Business School.

Tyler has more than two decades of experience with McKesson, having served in a wide variety of leadership roles throughout the company. He has led nearly every major business within the company as well as McKesson’s corporate strategy and business development unit.

Joined Varian as an intern in 1999, then full time in 2001, and has held multiple cross-functional roles and executive positions during two-decade tenure with the company. Intimate understanding of healthcare, software solutions, medical devices, technology trends, reimbursement trends and strategies that lead to success in targeted channel segments globally. Marketing strategy, new product launch, portfolio strategy, M&A, P&L, restructuring, government relations, and general management experience. Consistent creation of strategies and execution against operating plans, sales goals and market objectives, including extensive experience of both high growth and slow growth periods (turnaround plans) of Varian Medical Systems journey from $500M to over $3B. Including returning Varian to double digit growth following becoming President of the $3B+ P&L of Oncology systems. Strong leadership skills with a track record of creating an inspiring vision and communicating effectively both internally/externally through developing cultural, servant leadership and focusing on people/teams to drive net promoter scores to all-time highs and enable sustainable long-term success.